Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
This randomized controlled trial evaluated crocin (30 mg twice daily for 8 weeks) in 53 Parkinson's disease patients using movement rating scales and oxidative stress markers. The intervention showed statistically significant improvements in movement and daily activity scores, though oxidative DNA damage markers did not change significantly.
A post-hoc analysis of clinical trial data shows that extended-release amantadine significantly reduced OFF-related dystonia in Parkinson's disease patients over 12 weeks, with improvements sustained over 2 years. The benefit was independent of reduction in OFF time, suggesting a specific effect on dystonia symptoms.
This review addresses the lack of consensus definition for advanced Parkinson's disease by synthesizing clinical features (motor fluctuations, falls, cognitive decline), pathological burden markers, and neuroimaging findings associated with disease progression. The authors propose a longitudinal assessment model incorporating clinical markers and quality-of-life metrics to better characterize and predict disease trajectory in PD patients.
A 75-year-old woman with GBA mutation-associated Parkinson's disease initially responded well to L-Dopa but developed rapid motor decline, severe cognitive fluctuations, and dementia four years into disease course, progressing to death within one year. Autopsy confirmed pure Parkinson's pathology without concomitant Alzheimer's disease, demonstrating that sudden disease acceleration in PD does not necessarily require co-existent Alzheimer's pathology.
A prospective study of 45 Parkinson's disease patients with sleep disturbances compared safinamide and rasagiline, two monoamine oxidase-B inhibitors. Safinamide showed superior sleep improvements including increased deep sleep (N3), better sleep efficiency, and reduced periodic limb movements, with significant improvements on sleep quality scales, while rasagiline showed minimal sleep benefit despite motor symptom improvement in both groups.